Racotumomab
Racotumomab Basic information
- Product Name:
- Racotumomab
- Synonyms:
-
- Racotumomab
- Research Grade Racotumomab (DGK11201)
- Research Grade Racotumomab
- Racotumomab (anti-GM3)
- CAS:
- 946832-34-4
- MW:
- 0
- Mol File:
- Mol File
Racotumomab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Racotumomab Usage And Synthesis
Uses
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3].
in vivo
Racotumomab (50 μg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model[2].
Racotumomab (50 μg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft[3].
Racotumomab (50-200 μg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft[3].
| Animal Model: | 3LL cell (s.c.) mice xenograft[3] |
| Dosage: | 50 μg/dose, together with Pemetrexed (100 mg/kg) |
| Administration: | Subcutaneous injection (s.c.) |
| Result: | Reduced lung nodules. |
References
[1] Vázquez AM, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012 Oct 23;2:150. DOI:10.3389/fonc.2012.00150
[2] Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014 Apr;50(4):301-7. DOI:10.1358/dot.2014.50.4.2116670
[3] Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160. DOI:10.3389/fonc.2012.00160
[4] Truong CS, et al. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. Vaccines (Basel). 2022 Feb 4;10(2):240. DOI:10.3390/vaccines10020240
RacotumomabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com